Late-onset clozapine-induced agranulocytosis in a patient with comorbid multiple sclerosis. 2013

Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
Department of Psychiatry, National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore-560029, India. Electronic address: dhanya.ravi@gmail.com.

The risk of clozapine-induced agranulocytosis is highest in the initial 6 months after onset of treatment. There have been very few reports of neutropenia and agranulocytosis after this period. We report a unique case of delayed clozapine-induced agranulocytosis in a patient with preexisting multiple sclerosis (MS) which was treated with granulocyte colony-stimulating factor. Both MS and clozapine-induced agranulocytosis have an underlying autoimmune immune mechanism. This case highlights the need for frequent blood count monitoring on clozapine even after the initial 6 months of starting treatment especially in patients with a past history of drop in white blood cell counts as well as with a comorbid autoimmune disorder.

UI MeSH Term Description Entries
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D012563 Schizophrenia, Paranoid A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination. Delusional Disorder,Paranoid Schizophrenia,Delusional Disorders,Disorder, Delusional,Disorders, Delusional,Paranoid Schizophrenias,Schizophrenias, Paranoid
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
October 2014, Indian journal of psychological medicine,
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
June 2002, The Annals of pharmacotherapy,
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
October 2011, Journal of clinical psychopharmacology,
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
October 2003, Journal of clinical psychopharmacology,
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
September 2015, Psychiatria Danubina,
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
May 2006, Psychiatrische Praxis,
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
January 2020, Indian journal of psychiatry,
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
January 1997, Journal of neural transmission (Vienna, Austria : 1996),
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
March 2012, The neurologist,
Dhanya Raveendranathan, and Eesha Sharma, and Ganesan Venkatasubramanian, and Mukund G Rao, and Shivarama Varambally, and Bangalore N Gangadhar
May 2019, Cureus,
Copied contents to your clipboard!